Pharmaceutical compositions with antiflaviviral activity

US11491123B2 · kind B2 · utility

Assignees

• HEALTH RESEARCH, INC. · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Hongmin Li · Daguantang, CN
• Laura D. Kramer · Albany, US
• Zhong Li · Lo Wu, CN
• Ruili Huang · Rockville, US
• Menghang Xia · Rockville, US

Key dates

• Filing date: Jun 23, 2017
• Grant date: Nov 8, 2022
• Expiry date: Jun 23, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.